Comparative value-based pricing of an Ebola vaccine in resource-constrained countries based on cost-effectiveness analysis.
J Med Econ
; 25(1): 894-902, 2022.
Article
em En
| MEDLINE
| ID: mdl-35748085
In infectious diseases, issues related to pricing, affordability and access to interventions are very important; particularly in low-income countries (LIC) because of the scarcity of resources coupled with several competing priorities. Pricing interventions fairly in LICs facilitates the prevention and management of infectious diseases, promotes innovation, and ensures patient access to valuable interventions. We were interested in determining a fair price of an intervention for an infectious disease (here, vaccination against Ebola virus disease) based on the cost-effectiveness (or value) of vaccination in four African countries.Using data from EVD outbreaks in Liberia, the Democratic Republic of Congo, Uganda, and Sierra Leone, we estimated the number of susceptible people who were exposed to the virus, became infected, recovered, or died. We did this for two scenarios: not vaccinating versus vaccinating to achieve herd immunity. We determined how many disability-adjusted life years (DALY; loss of the equivalent of a year of full health) would be prevented by vaccination; setting this as our value metric. Using this value metric and percentages of the gross domestic product (GDP) per capita as the willingness-to-pay (WTP) threshold (the price a payer might be prepared to pay for the intervention) we demonstrate how to calculate the maximum price for the vaccine package.The combination of greater effectiveness (DALYs averted), greater cost-effectiveness (value) and higher GDP per capita (WTP) resulted in different price ceilings in the four countries. The method proposed here is easy to understand and requires minimum data to determine a price for an intervention's price based on its value.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Contexto em Saúde:
11_ODS3_cobertura_universal
/
1_ASSA2030
/
2_ODS3
Problema de saúde:
11_financial_arrangements
/
1_financiamento_saude
/
1_medicamentos_vacinas_tecnologias
/
2_cobertura_universal
Assunto principal:
Doença pelo Vírus Ebola
/
Vacinas contra Ebola
Tipo de estudo:
Health_economic_evaluation
/
Prognostic_studies
Aspecto:
Patient_preference
Limite:
Humans
Idioma:
En
Revista:
J Med Econ
Assunto da revista:
SERVICOS DE SAUDE
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Estados Unidos